Genelux Q1 EPS Decreased by Brookline Capital Management

Genelux Co. (NASDAQ:GNLX) – Research analysts at Brookline Capital Management decreased their Q1 2025 earnings per share estimates for Genelux in a report issued on Monday, March 31st. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.23) for the quarter, down from their previous forecast of ($0.20). The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.86) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Genelux in a report on Monday, March 31st. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Genelux currently has a consensus rating of “Buy” and an average price target of $18.25.

Genelux Price Performance

GNLX stock opened at $2.39 on Thursday. The firm has a market cap of $83.00 million, a PE ratio of -2.52 and a beta of -1.41. Genelux has a 12 month low of $1.60 and a 12 month high of $5.89. The firm has a 50 day simple moving average of $4.00 and a 200 day simple moving average of $3.10.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09).

Institutional Trading of Genelux

Hedge funds have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in shares of Genelux in the fourth quarter worth approximately $25,000. Apollon Wealth Management LLC boosted its stake in Genelux by 20.4% in the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after purchasing an additional 2,857 shares during the period. Raymond James Financial Inc. purchased a new position in Genelux during the 4th quarter worth approximately $41,000. D.A. Davidson & CO. acquired a new stake in Genelux during the 4th quarter valued at $51,000. Finally, XTX Topco Ltd purchased a new stake in shares of Genelux in the third quarter valued at $59,000. 37.33% of the stock is owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.